Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests

Thrombosis Research

Volumn 129, Issue 5, 2012, Pages 616-622

  Gremmel, Thomas ^a   Kopp, Christoph W ^a   Moertl, Deddo ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a   Mannhalter, Christine ^a   Steiner, Sabine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clopidogrel; CYP2C19; platelet function testing

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19;

AGED; ALLELE; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ELECTRODE AGGREGOMETRY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STENT;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; FEMALE; GENOTYPE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE;

EID: 84860451417     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.11.019     Document Type: Article

References (41)

1. M. Cattaneo P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents Eur Heart J 27 2006 1010 1012
2. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
3. T. Geisler, H. Langer, M. Wydymus, K. Gohring, C. Zurn, and B. Bigalke Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425
4. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
5. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
6. P.A. Gurbel, K.P. Bliden, K. Guyer, P.W. Cho, K.A. Zaman, and R.P. Kreutz Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
7. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, and A. Schomig Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
8. L. Bonello, F. Paganelli, M. Arpin-Bornet, P. Auquier, J. Sampol, and F. Dignat-George Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events J Thromb Haemost 5 2007 1630 1636
9. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, and C. Giglioli Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
10. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
11. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
12. A.D. Michelson, A.L. Frelinger III, E. Braunwald, W.E. Downey, D.J. Angiolillo, and N.P. Xenopoulos TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
13. R.F. Storey, D.J. Angiolillo, S.B. Patil, B. Desai, R. Ecob, and S. Husted Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
14. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel J Thromb Haemost 8 2010 37 42
15. D.J. Angiolillo, S.B. Shoemaker, B. Desai, H. Yuan, R.K. Charlton, and E. Bernardo Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716
16. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition Heart 96 2010 186 189
17. M. Gilard, B. Arnaud, G. Le Gal, J.F. Abgrall, and J. Boschat Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin J Thromb Haemost 4 2006 2508 2509
18. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
19. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
20. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
21. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, and J. Stegherr Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
22. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
23. D. Sibbing, D. Gebhard, W. Koch, S. Braun, J. Stegherr, and T. Morath Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy J Thromb Haemost 8 2010 1685 1693
24. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation Thromb Haemost 101 2009 333 339
25. M. Lordkipanidzé, C. Pharand, T.A. Nguyen, E. Schampaert, D.A. Palisaitis, and J.G. Diodati Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients Eur Heart J 29 2008 2877 2885
26. B. Linnemann, J. Schwonberg, H. Mani, S. Prochnow, and E. Lindhoff-Last Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary J Thromb Haemost 6 2008 677 683
27. B. Shenkman, S. Matetzky, P. Fefer, H. Hod, Y. Einav, and A. Lubetsky Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests Thromb Res 122 2008 336 345
28. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
29. N.J. Breet, J.W. van Werkum, H.J. Bouman, J.C. Kelder, H.J. Ruven, and E.T. Bal Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
30. U.S. Tantry, K.P. Bliden, C. Wei, R.F. Storey, M. Armstrong, and K. Butler First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: The ONSET/OFFSET and RESPOND genotype studies Circ Cardiovasc Genet 3 2010 556 566
31. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, and O. Barthélémy Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systemic meta-analysis J Am Coll Cardiol 56 2010 134 143
32. F. Sofi, B. Giusti, R. Marcucci, A.M. Gori, R. Abbate, and G.F. Gensini Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis Pharmacogenomics J 2011 epub ahead of print.
33. W. Hochholzer, D. Trenk, M.F. Fromm, C.M. Valina, C. Stratz, and H.P. Bestehorn Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
34. S. Ghannudi, P. Ohlmann, N. Meyer, M. Wiesel, B. Radulescu, and M. Chauvin Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry J Am Coll Cardiol 3 2010 648 656
35. C. Frere, T. Cuisset, B. Gaborit, M.C. Alessi, and J.S. Hulot The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome J Thromb Haemost 7 2009 1409 1411
36. R. Paniccia, E. Antonucci, A.M. Gori, R. Marcucci, C. Giglioli, and D. Antoniucci Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients J Thromb Haemost 5 2007 1839 1847
37. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, and C. Giglioli High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting Thromb Haemost 104 2010 279 286
38. R. Paniccia, E. Antonucci, N. Maggini, M. Miranda, E. Romano, and A.M. Gori Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study Ther Drug Monit 33 2011 94 98
39. M.L. Kalb, L. Potura, G. Scharbert, and S.A. Kozek-Langenecker The effect of ex vivo anticoagulants on whole blood platelet aggregation Platelets 20 2009 7 11
40. G. Helft, J.I. Osende, S.G. Worthley, A.G. Zaman, O.J. Rodriguez, and E.I. Lev Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin Arterioscler Thromb Vasc Biol 20 2000 2316 2321
41. J.M. Siller-Matula, K. Haberl, K. Prillinger, S. Panzer, I. Lang, and B. Jilma The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation Thromb Res 123 2009 874 880